Welcome to our dedicated page for Imunon news (Ticker: IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Imunon, Inc. (IMNN) generates frequent news as a clinical-stage biotechnology company advancing DNA-mediated immunotherapies and DNA vaccine technologies. Most coverage centers on its lead program, IMNN-001, a TheraPlas-based IL-12 DNA immunotherapy in Phase 3 development for newly diagnosed advanced ovarian cancer, and on its PlaCCine DNA vaccine platform, including the IMNN-101 COVID-19 booster candidate.
Investors following IMNN news can expect regular updates on clinical trial progress, such as enrollment milestones, translational data and survival outcomes from the OVATION 2 Phase 2 study and the pivotal OVATION 3 Phase 3 trial. Company releases describe how IMNN-001 is being evaluated in combination with standard neoadjuvant and adjuvant chemotherapy, and how biomarker data show shifts in the tumor microenvironment toward more active anti-tumor immunity.
Another major news theme is scientific and medical conference activity. Imunon frequently announces posters and presentations at meetings such as the Society for Immunotherapy of Cancer, the European Society for Medical Oncology, the International Gynecologic Cancer Society and specialized ovarian cancer conferences. These items often include new translational data on immune cell changes, cytokine profiles and clinical outcomes associated with IMNN-001.
Imunon also issues news on corporate and financial developments, including quarterly financial results, R&D Day events, capital markets transactions like registered direct offerings and at-the-market equity programs, and Nasdaq listing-related updates. For the PlaCCine platform, news items highlight proof-of-concept data for IMNN-101 and presentations at international vaccine conferences.
For readers tracking IMNN, this news feed provides a consolidated view of clinical milestones, scientific recognition, financing activities and regulatory communications that shape the company’s development trajectory in oncology and DNA vaccine research.
IMUNON (Nasdaq: IMNN) reported 2025 results and clinical progress on IMNN-001 for newly diagnosed advanced ovarian cancer. Final Phase 2 OVATION 2 data show continued median overall survival improvement: 14.7 months benefit (45.1 vs. 30.4 months) versus standard of care, and 24.2 months with PARP inhibitor maintenance (65.6 vs. 41.4 months).
Corporate actions include a December 2025 at-the-market registered direct offering (~$7.0M) and a strategic reorganization; 2025 net loss was $14.5M and year-end cash was $8.8M.
IMUNON (Nasdaq: IMNN) reported final Phase 2 OVATION 2 results showing an improved median overall survival (OS) benefit for IMNN-001 plus standard chemotherapy: a 14.7-month OS increase (45.1 vs. 30.4 months) versus SoC alone. Women receiving IMNN-001 plus PARP inhibitor maintenance showed a 24.2-month OS increase (65.6 vs. 41.4 months).
OVATION 2 randomized 112 patients. IMUNON says Phase 3 OVATION 3 enrollment is ahead of plan, currently open at seven sites with up to 43 sites considered and ~80 patients (~20% of 500 target) expected within a year; two interim OS analyses are planned.
IMUNON (Nasdaq: IMNN) will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its Phase 3 clinical program for IMNN-001.
To join, dial 800-715-9871 (North America/Toll Free) or 646-307-1963 (U.S./Toll) and reference Conference ID 4157104; a live webcast and a 90-day audio replay will be available. According to the company, the call will review 2025 results and clinical progress for IMNN-001.
IMUNON (Nasdaq: IMNN) announced a strategic reorganization to reduce nonessential headcount and redefine roles to lower operating expenses and prioritize its pivotal OVATION 3 Phase 3 ovarian cancer trial.
The company said Phase 3 enrollment remains ahead of schedule, and EVP/CSO Khursheed Anwer will retire effective February 20, 2026.
IMUNON (Nasdaq: IMNN) announced a registered direct offering to a single healthcare institutional investor for 1,939,114 shares of common stock (or pre-funded warrants) plus warrants to purchase up to 1,939,114 shares, at a combined purchase price of $3.61 per share and warrant (pre-funded warrant alternative at $3.6099).
The offering is expected to yield approximately $7.0 million gross, with warrants exercisable immediately at $3.482 and expiring five years from issuance; pre-funded warrants have a $0.0001 exercise price and do not expire. The offering will be made under the company’s Form S-3 shelf declared effective May 22, 2024, and is expected to close on or about December 31, 2025.
IMUNON (Nasdaq: IMNN) reported 2025 clinical and operational progress as it advances the pivotal Phase 3 OVATION 3 study of IMNN-001 in newly diagnosed advanced ovarian cancer and prepares toward a potential BLA filing. Key Phase 2 results cited include a 13-month median overall survival (OS) extension (HR 0.70) and an HR of 0.42 in a PARP inhibitor maintenance subgroup. Ongoing MRD translational data show IL-12 induction in macrophages, tumor microenvironment inflammation, lower MRD positivity and improved CRS/PFS signals. Company cites cost reductions in cGMP manufacturing and estimates $30 million to fund OVATION 3 HRD+ subgroup activities. Fast Track and Orphan Drug designations remain in place.
IMUNON (NASDAQ: IMNN) reported third quarter 2025 results and clinical progress on November 13, 2025. The company highlighted a median 13-month overall survival (OS) benefit observed with IMNN-001 in OVATION 2 and translational data showing tumor microenvironment shifts (CD8+ increases, reduced IDO/PD-L1/Treg) in 50-80% and 65-80% of paired samples. IMUNON described expanded Phase 3 OVATION 3 enrollment and an adaptive, event-driven trial design aligned with FDA precedents.
Financially, Q3 net loss was $3.4M (vs $4.8M prior year), operating expenses fell ~30%, and cash was $5.3M, which the company says funds operations into Q1 2026 while it pursues selective financing.
IMUNON (Nasdaq: IMNN) hosted a public webcast on Nov 10, 2025 presenting translational and clinical data for its DNA-mediated immunotherapy IMNN-001.
Speakers included cancer key opinion leaders, principal investigators from the Phase 3 OVATION 3 and Phase 2 MRD trials, clinicians, statistical experts and IMUNON executives. The event highlighted clinical findings that the company described as showing significant potential for women with advanced ovarian cancer.
A recording and symposium slides are available on IMUNON’s Scientific Presentations page at https://investors.imunon.com/scientific-presentations.
IMUNON (Nasdaq: IMNN) held an R&D Day on Nov 10, 2025 in New York to present clinical updates for its DNA-mediated immunotherapy IMNN-001 in newly diagnosed advanced ovarian cancer.
Presentations reviewed Phase 2 OVATION 2 and an MRD study, highlighted a reported median 13-month overall survival (OS) benefit for IMNN-001 plus standard-of-care chemotherapy, safety and tolerability data, translational findings on tumor microenvironment remodeling, and progress on the pivotal Phase 3 OVATION 3 trial including activation and enrollment updates. A live webcast and materials were made available on the company scientific presentations page.
IMUNON (Nasdaq: IMNN) will host an R&D Day on Monday, November 10, 2025 at 8:00 a.m. ET in New York City with a live webcast option. The event features principal investigators discussing clinical progress for IMNN-001, a DNA-mediated IL-12 immunotherapy in Phase 3 development for advanced ovarian cancer, plus Phase 2 MRD results and Phase 3 statistical design.
Speakers include investigators from Washington University, MD Anderson, Berry Consultants, and IMUNON leadership covering OVATION 3/OVATION 2 data, MRD trial immune activation, trial design, enrollment momentum, and near-term clinical milestones. Registration is required to attend in person or virtually.